Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$48K, compared with $29.38M a year earlier. Trailing-twelve-month gross profit was $41.35M. Over 3 fiscal years it compounded at -32.2% a year.

Context

  • Gross profit amounted to 95.5% of revenue in FY2025, down 4.5 pp from a year earlier.
  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$48K or moves back toward the trailing-twelve-month quarterly average of $10.34M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$48K-101.6% QoQ
Last fiscal yearDec 2025
$64.2M-53.6% YoY
LTMMar 2026
$41.35M-69.4% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.2%——
1 year-53.6%——
3-year CAGR-32.2%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
64.2M USD
Year-over-year change
-53.6%
4-year CAGR
+51.0%

Gross Profit vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -69.4% is the 8th highest of 10, against a peer median of -36.4%.
  • Gross profit amounts to 91.2% of revenue for ARCT, versus a peer median of 87.2%.
ARCT Competitors
Gross Profit for ARCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVAXNovavax, Inc.LTM Mar 2026$504.72M USD-54.0%+14.8%84.6%
ABUSArbutus Biopharma CorporationLTM Mar 2026$191.41M USD+1784.1%-29.4%100.0%
VIRVir Biotechnology, Inc.LTM Mar 2026$180.27M USD+137.1%-61.5%275.2%
VALNValneva SELTM Mar 2026€46.05M EUR-46.8%+22.4%29.5%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$41.35M USD-69.4%-32.2%91.2%
PRQRProQR Therapeutics N.V.LTM Mar 2026€12.06M EUR-36.4%+52.2%89.7%
SLNSilence Therapeutics plcLTM Mar 2026$612.12K USD—-62.8%66.4%
BNTCBenitec Biopharma Inc.LTM Mar 2026-$475K USD-28.7%——
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$2.15M USD+8.3%——
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$2.24M USD-69.6%-81.5%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$40.76M USD-72.9%——
Peer median (excluding ARCT) —-36.4%-29.4%87.2%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.36M205.76M157.75M138.39M67.22M
Cost of Revenue00003.03M
Gross Profit12.36M205.76M157.75M138.39M64.2M
Gross Margin100.0%100.0%100.0%100.0%95.5%
Research & Development173.76M147.75M192.13M195.16M112.21M
Selling, General & Admin41.45M46.07M52.87M52.82M46.08M
Operating Expenses215.21M193.58M235.95M234.06M139.15M
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
EBITDA(199.81M)15.17M(24.17M)(77.4M)(62.76M)
EBITDA Margin-1616.7%7.4%-15.3%-55.9%-93.4%
Operating Income(202.85M)12.18M(78.21M)(95.67M)(74.96M)
Operating Margin-1641.3%5.9%-49.6%-69.1%-111.5%
Interest Income753K2.58M17.36M15.2M10.1M
Interest Expense2.67M3M767K00
Other Income / Expenses(822K)(1.53M)50.32M14.72M9.17M
Income Before Tax(203.67M)10.64M(27.89M)(80.95M)(65.78M)
Pre-Tax Margin-1648.0%5.2%-17.7%-58.5%-97.9%
Income Tax Expense01.3M1.84M(4K)0
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Net Margin-1648.0%4.5%-18.8%-58.5%-97.9%
EPS (Basic)(7.74)0.35(1.12)(3.00)(2.40)
EPS (Diluted)(7.74)0.35(1.12)(3.00)(2.40)
Weighted Avg Shares26.32M26.45M26.63M27M27.39M
Weighted Avg Shares (Diluted)26.32M27.09M26.63M27M27.39M

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.